Feb 23- The U.S. Food and Drug Administration on Monday approved Novartis AG's drug to treat patients who have relapsed after earlier therapies for multiple myeloma, an aggressive blood cancer, even though an advisory panel in November recommended against approval. Farydak was approved for use in combination with Takeda Pharmaceutical Co Ltd's Velcade and...